"Genting Shine (01952.HK) Icosapent ethyl approved for listing in South Korea, deepening Asian market development to release commercial value."

According to Zhidao Finance APP, on May 25, Hong Kong-listed innovative pharmaceutical company Union New Yao (01952.HK) announced that the South Korean Ministry of Food and Drug Safety (MFDS) has officially approved the new drug application (NDA) for Velspity (Chinese mainland Chinese name Vishi Ping), which is used to treat moderate to severe active ulcerative colitis in adults who have inadequate response, loss of response, or intolerance to traditional treatments (such as corticosteroids or immunosuppressants) or biologics.